Pathogenic mechanisms underlying SLC6A1 variant-mediated neurodevelopmental disorders
- 20 July 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in Brain
- Vol. 144 (8), 2237-2239
- https://doi.org/10.1093/brain/awab259
Abstract
Jennifer Z Cheng, Gemma L Carvill; Pathogenic mechanisms underlying SLC6A1 variant-mediated neurodevelopmental disorders, Brain, , awab259, https://doi.org/10.1This publication has 9 references indexed in Scilit:
- Common molecular mechanisms ofSLC6A1variant-mediated neurodevelopmental disorders in astrocytes and neuronsBrain, 2021
- Current knowledge of SLC6A1-related neurodevelopmental disordersBrain Communications, 2020
- Overexpressing wild‐type γ2 subunits rescued the seizure phenotype in Gabrg2+/Q390X Dravet syndrome miceEpilepsia, 2017
- Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic SeizuresAmerican Journal of Human Genetics, 2015
- Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectivesFrontiers in Cellular Neuroscience, 2014
- GABA Transporter-1 Deficiency Confers Schizophrenia-Like Behavioral PhenotypesPLOS ONE, 2013
- GABA Transporter-1 (GAT1)-Deficient Mice: Differential Tonic Activation of GABAA Versus GABAB Receptors in the HippocampusJournal of Neurophysiology, 2003
- GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortexJournal of Neuroscience, 1995
- Cloning of the human brain GABA transporterFEBS Letters, 1990